Sorrento Therapeutics

Description: 

Developing novel immunotherapies against medically-relevant targets utilizing Sorrento’s unique portfolio of proprietary OnTarget antibody technologies.  Sorrento is an antibody-centric, clinical stage biopharmaceutical company focused on the discovery and development of safe and effective immunotherapies for oncology and autoimmune/inflammation diseases. Sorrento’s lead programs consist of four Phase III BioSimilar/BioBetter antibodies, and two Phase I CAR-T programs for treatment of solid tumors. Sorrento also is advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).

Location(s): 
San Diego CA
United States